Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of desensitization therapy, which includes
VELCADE® (bortezomib) and plasmapheresis, on select sensitized patients awaiting heart
transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)